The partnership de-risks early-stage development by leveraging WuXi XDC’s ADC expertise, but without disclosed funding or milestone payments, near-term financial impact is limited. Traders should monitor for future IND submission and Phase 1 initiation as key catalysts.
Price Chart
Executive Summary
Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate the development of its novel PH1 payload for its lead antibody-drug conjugate (ADC) candidate, AKTX-101, targeting metastatic urothelial cancer. The collaboration leverages WuXi XDC's expertise in ADC development and manufacturing to advance Akari’s preclinical program toward a Phase 1 trial expected in late 2026 or early 2027.
Key Facts
- Akari Therapeutics partnered with WuXi XDC to develop its PH1 payload for AKTX-101, an ADC targeting metastatic urothelial cancer.
- PH1 is a novel spliceosome modulator payload that disrupts RNA splicing in cancer cells, differentiating it from traditional ADCs.
- Preclinical studies show AKTX-101 has superior anti-tumor regression and complete remissions compared to other ADCs.
- Phase 1 clinical trial initiation is expected in late 2026 or early 2027, subject to regulatory clearance.
- No financial terms of the partnership were disclosed.
Financial Impact
undisclosed amount
Risk Factors
- Clinical development risk: AKTX-101 has not yet entered human trials.
- No financial terms disclosed — potential lack of immediate capital infusion.
- Dependence on successful regulatory clearance and trial initiation timelines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.52 (−2.29%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.52 (−2.29%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.52 (+13.00%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.52 (+36.51%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.52 (−40.04%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.52 (+18.16%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.52 (−12.07%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.52 (−12.07%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.52 (−61.36%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.52 (+52.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers